81 results
424B3
HOTH
Hoth Therapeutics Inc
22 Apr 24
Prospectus supplement
4:15pm
incurred losses and expect to continue to operate at a net loss for at least the next several years as we commence our research and development efforts … adequate funds to satisfy our capital requirements, we may have to delay, scale back or eliminate our research and development activities, clinical studies
8-K
EX-99.1
HOTH
Hoth Therapeutics Inc
28 Mar 24
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
7:00am
, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research … and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner
8-K
EX-99.1
1vpa 4n2v
15 Sep 23
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:15pm
8-K
EX-99.2
iwjtt149etiirr 353
15 Sep 23
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:15pm
424B5
votwg
14 Sep 23
Prospectus supplement for primary offering
5:24pm
8-K
EX-99.1
e39w383 puo90gw6fix
30 Dec 22
Hoth Therapeutics Announces $10 Million Private Placement
4:15pm
UPLOAD
mbwus 5hj
7 Dec 22
Letter from SEC
12:00am
8-K
EX-99.1
5oor2gy2anmhsmjzdg
10 Nov 22
Other Events
8:00am
8-K
EX-99.1
pjpcis9c2y2 btrl0ux0
24 Oct 22
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
EX-99.1
rbf0t k2f2
29 Apr 22
Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs APRIL 2022
4:16pm